DOI: https://doi.org/10.14710/dimj.v4i2.18393

Effect of DLBS3233, Metformin, and Their Combination on the Expressions of VEGF and Endometriosis Implants in Endometriosis Mice (A Mouse Model in Endometriosis Study)

*Setya Girindra Wardana  -  Resident of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, RSUP dr. Kariadi, Semarang, Indonesia, Indonesia
Yuli Trisetiyono  -  Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, dr. Kariadi, Semarang, Indonesia, Indonesia
Raden Soerjo Hadijono  -  Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, dr. Kariadi, Semarang, Indonesia, Indonesia
Inu Mulyantoro  -  Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, dr. Kariadi, Semarang, Indonesia, Indonesia
Ratnasari Dwi Cahyanti  -  Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, dr. Kariadi, Semarang, Indonesia, Indonesia
Julian Dewantiningrum  -  Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, dr. Kariadi, Semarang, Indonesia, Indonesia
Open Access Copyright (c) 2023 Diponegoro International Medical Journal
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Abstract

 

Background: Endometriosis is a gynaecological disorder characterized by the presence of endometrial tissue outside the uterine cavity. The process of angiogenesis is regulated by VEGF which plays an important role in the development of endometriosis implants. Metformin is an insulin sensitizer that is known to have a beneficial effect in the treatment of endometriosis and DLBS3233 is a PPARγ agonist, it is hoped that it can reduce VEGF and reduce endometrial implants..

Objective: To explore the effect of DLBS3233, metformin, and combination on VEGF expression and endometrial implant area of endometriosis-induced mice.

Methods: This experimental study used 3-months old 28 BALB/c mice of endometriosis that were randomly and equally divided into four groups (K, P1, P2, and P3). On the 15th day, the K group was given a placebo, the P1 group was given DLBS3233 0.25 mg/day for 14 days, the P2 group was given metformin 4 mg/day for 14 days and the P3 group was given a combination. The immunohistochemistry of VEGF expression was performed from the abdominal cavity and pelvic peritoneal tissues of the mice and measured by the Remmele Scale Index, while the extracted mice's endometrial implants were analyzed with a computer tracing method. All data normality tests were calculated with the Shapiro-Wilk test. The mean difference test of all groups was analyzed using the one-way ANOVA test and the Kruskal-Wallis test.

Results: There were significant differences in the expressions of VEGF (p=0.005) and endometrial implants (p=0.001). Expression of VEGF in the P3 group was significantly lower compared to others and endometrial implant area in the P2 group was significantly lower compared to others.

Conclusion: DLBS3233 and Metformin may be a potentially effective drug treatments for endometriosis by decreasing VEGF expression and endometrial implants.

 

Keywords: DLBS3233, Endometriosis, Metformin, VEGF
Fulltext View|Download
Keywords: DLBS3233; Endometriosis; Metformin; VEGF

Article Metrics:

Article Info
Section: Original Research Article
Language : EN
Recent articles
RISK FACTORS FOR SMELL AND TASTE DISORDER IN MILD AND MODERATE COVID-19 IN SEMARANG RECURRENCE IN NON-EPITHELIAL OVARIAN CANCER PATIENTS AT RSUP DR. KARIADI SEMARANG Incident Rate of Vesicovaginal Fistula at Dr. Kariadi General Hospital Semarang in 2022 Intraoperative Endoscopy as Guidance for Adequate Myotomy in Laparoscopic Heller Procedure: A Rare Case Report More recent articles
  1. HIFERY. Consensus on Management of Menstrual Pain in Endometriosis. 2013;12–4
  2. Speroff L, Fritz MA. endometriosis. Clinical Gynecologic Endocrinology and Infertility. 9 ed. Philadelphia: Lippincott Williams & Wilkins; 2020. 1221-48
  3. Greaves E, Cousins FL, Murray A, Esnal-Zufiaurre A, Fassbender A, Horne AW, et al. A novel mouse model of endometriosis mimics human phenotype and reveals insights into the inflammatory contribution of shed endometrium. Am J Pathol. 2014;184(7):1930–9
  4. Samimi M, Pourhanifeh MH, Mehdizadehkashi A, Eftekhar T, Asemi Z. The role of inflammation, oxidative stress, angiogenesis, and apoptosis in the pathophysiology of endometriosis: Basic science and new insights based on gene expression. J Cell Physiol. 2019;234(11):19384–92
  5. Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertile Sterile. 2017;107(3):555–65
  6. Foda AA, Aal IAA. Metformin as a new therapy for endometriosis, its effects on both clinical picture and cytokines profile. Middle East Fertil Soc J. 2012 Dec;17(4):262–7
  7. Stochino-Loi E, Major AL, Gillon TER, Ayoubi JM, Feki A, Bouquet de Joliniere J. Metformin, the Rise of a New Medical Therapy for Endometriosis? A Systematic Review of the Literature. Front Med. 2021;8(May):1–5
  8. Nailufar F, Tandrasasmita OM, Tjandrawinata RR. DLBS3233 increases glucose uptake by mediating upregulation of PPARγ and PPARδ expression. Biomed Prev Nutr. 2011 Apr;1(2):71–8
  9. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F, et al. PPAR activators inhibit endothelial cell migration by targeting AktBiochem Biophys Res Commun . 2002;293(5):1431-7
  10. Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: A prospective, randomized, placebo- and drug-controlled study. Fertile Sterile. 2007;88:1108–19
  11. Mulyantoro I, Noerpramono NP, Febrianto YH, Widjiati, Purwati, et al. Effect of adipose derived mesenchymal stem cells on the expression of Bax2, Ki67, TNF alpha, vegf in metformin. Turk J Immunol 2021;9(1):36-49
  12. Xu JN, Zeng C, Zhou Y, Peng C, Zhou YF, Xue Q. Metformin inhibits StAR expression in human endometriotic stromal cells via AMPK-mediated disruption of CREB-CRTC2 complex formation. J Clin Endocrinol Metab. 2014;99(8):2795–803
  13. Becker CM, D'Amato RJ. Angiogenesis and antiangiogenic therapy in endometriosis. Vol. 74, Microvascular Research. 2007.p. 121–30
  14. Indrapraja O, Mulyantoro I, Widjiati W, Noerpramana NP. Effect of Metformin on Bcl-2/Bax Expression Ratio and Endometrial Implants: A Mouse Model in Endometriosis Study. J Biomed Translate Res. 2020;6(2):53–8
  15. Lebovic DI, Kavoussi SK, Lee JH, Banu SK, Arosh JA. PPARγ activation inhibits growth and survival of human endometriotic cells by suppressing estrogen biosynthesis and PGE2 signaling. Endocrinology. 2013;154(12):4803–13
  16. Garikapati KK, Ammu VVVRK, Krishnamurthy PT, Chintamaneni PK, Pindiprolu S Kiran SS. Possible role of Thiazolidinediones in the management of Type-II Endometrial Cancer. Med Hypotheses. 2019;126:78–81
  17. Freeman, AM, & Pennings, N. Insulin resistance. In StatPearls. StatPearls Publishing. 2022

Last update:

No citation recorded.

Last update:

No citation recorded.